CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC [0.03%]
CheckMate-722：Nivolumab联合化疗在TKI耐药EGFR突变型NSCLC患者中的崛起与陨落
Alexandria T M Lee,Misako Nagasaka
Alexandria T M Lee
The treatment of non-small cell lung cancer (NSCLC) has increasingly been driven by the presence of targetable driver mutations, including epidermal growth factor receptor (EGFR) mutations. Tyrosine receptor inhibitors (TKIs) have subsequen...
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code [0.03%]
代码破解200：针对KRAS G12C突变型非小细胞肺癌的索托雷塞（AMG510）取得了突破性进展
Danielle Brazel,Jennifer Kim,Sai-Hong Ignatius Ou
Danielle Brazel
Per the US FDA sotorasib approval summary, KRAS G12C mutation is found in approximately 14% of adenocarcinoma of the lung, primarily in patients with a history of smoking. Until recently, targeted therapies against KRAS G12C have been large...
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code [0.03%]
突破200：Sotorasib并未破解KRASG12C难题密码
Shannon S Zhang,Alexandria Lee,Misako Nagasaka
Shannon S Zhang
Thirteen percent of non-small cell lung cancer (NSCLC) patients are estimated to have the KRAS G12C mutation. Sotorasib is a novel KRAS G12C inhibitor that has shown promising results in preclinical and clinical studies, granting its condit...
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review [0.03%]
液态活检基因分型在肺癌的临床效用及应用：全面综述
Maria Concetta Nigro,Paola Valeria Marchese,Chiara Deiana et al.
Maria Concetta Nigro et al.
Precision medicine has revolutionized the therapeutic management of cancer patients with a major impact on non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, where advances have been remarkable. Tissue biopsy, required fo...
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno [0.03%]
Tiragolumab（抗TIGIT）在SCLC中的应用：Skyscraper-02，一场滔天大火
Danielle Brazel,Sai-Hong Ignatius Ou,Misako Nagasaka
Danielle Brazel
Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) p...
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib [0.03%]
NSCLC中KRAS突变的长期靶向治疗：聚焦于Adagrasib
Danielle Brazel,Zhaohui Arter,Misako Nagasaka
Danielle Brazel
KRASG12C is one of the most common oncogenes in non-small cell lung cancer (NSCLC) and is associated with a poor prognosis. Historically, KRAS mutations have been difficult to target due to lack of binding sites and exceptionally high affin...
Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs? [0.03%]
富蒙替尼（Af Fluxitinib，AST2818）亮点评析——三代EGFR-TKIs中的瑞士军刀（del19、L858R、T790M、Exon 20插入突变及“少见”G719X、S768I、L861Q）？
Shannon S Zhang,Sai-Hong Ignatius Ou
Shannon S Zhang
Osimertinib, a third-generation (3G) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is now considered the standard of care for the first-line (1L) treatment of advanced EGFR+ NSCLC due to statistically significant i...
Joséphine Carpentier,Iuliia Pavlyk,Uma Mukherjee et al.
Joséphine Carpentier et al.
Arginine deprivation has gained increasing traction as a novel and safe antimetabolite strategy for the treatment of several hard-to-treat cancers characterised by a critical dependency on arginine. Small cell lung cancer (SCLC) displays ma...
Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC [0.03%]
解析ADAURA研究：在EGFR突变型II至IIIA期非小细胞肺癌患者中，目前还不能放弃以铂类为基础的辅助化疗
Danielle Brazel,Misako Nagasaka
Danielle Brazel
Recently, the ADAURA study demonstrated statistically significant improved disease-free survival (DFS) with adjuvant osimertinib in patients with resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring an epidermal growth factor...
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation [0.03%]
tepotinib和capmatinib治疗非小细胞肺癌MET外显子14跳跃突变患者的疗效分析
Danielle Brazel,Shannon Zhang,Misako Nagasaka
Danielle Brazel
Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed, amplified, or mutated in 1-20% of NSCLC. MET dysregulation is associated with a poor prognosis. Recently, development of targeted therapies against MET exon ...